FDA Brief

Warning letters Drugs

FDA warning letter to

kubapharm.com

High riskIssued Mar 30, 2022Posted Apr 12, 2022Center for Drug Evaluation and Research | CDER

FDA and DEA warned kubapharm.com it unlawfully sells high-abuse-risk stimulants, including Adderall, online without required registrations or prescriptions.

What happened

FDA reviewed the website and DEA reviewed its operations; no inspection is mentioned. The agencies found kubapharm.com offered amphetamine products such as "Buy Adderall Online Now" and advertised Schedule II controlled substances (drugs with high abuse potential) to U.S. consumers. DEA determined the site had no modified DEA registration (special registration for online sales of controlled substances), and FDA found the prescription drug offered without a prescription, making it misbranded (unlawfully labeled or sold under federal drug rules).

What FDA found

  1. The website offered to distribute or dispense Schedule II stimulants, including amphetamine products, over the Internet without a modified DEA registration.

    21 U.S.C. § 841(h)
  2. The website advertised controlled substances online and directed prospective buyers to Internet sellers that lacked valid modified DEA registration.

    21 U.S.C. § 843(c)(2)(A)
  3. It offered Adderall, a prescription drug, for sale without requiring a prescription.

    FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]
  4. Offering the prescription drug without a prescription made the drug misbranded while held for sale.

    FD&C Act § 301(k) [21 U.S.C. § 331(k)]
  5. The website caused misbranded drugs to be introduced into interstate commerce.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA and DEA ask the company to take corrective action and notify both agencies in writing within 15 working days of receipt, with an explanation of each step and related documents; if it disagrees, it should send its reasoning and supporting information within that time.

Who should pay attention

  • online pharmacies and websites selling prescription drugs
  • telehealth and e-commerce platforms that connect buyers to controlled substances
  • makers and distributors of Adderall and other Schedule II stimulants

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Celmade

    FDA warned Celmade over websites selling unapproved, misbranded injectable botulinum toxin products to U.S. consumers.

    High risk
  2. Ketacyn Pharmaceuticals / www.ketacynpharma.com

    FDA told Ketacyn Pharmaceuticals to stop selling unapproved ketamine injection and ketamine gummies to U.S. consumers online.

    High risk
  3. Extra Medication / www.extramedication.com

    FDA warned website Extra Medication for selling unapproved, misbranded ketamine drugs to U.S. consumers without prescriptions.

    High risk
  4. Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com

    FDA warned Pure Arylcyclohexylamine Store it sells unapproved, misbranded ketamine drugs, including an injectable, to U.S. consumers online.

    High risk